- Home
- ENVB vs SILO Comparison
ENVB vs SILO Comparison
Compare ENVB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- SILO
- Stock Information
- Founded
- ENVB 1994
- SILO 2010
- Country
- ENVB United States
- SILO United States
- Employees
- ENVB N/A
- SILO N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- ENVB Health Care
- SILO Consumer Discretionary
- Exchange
- ENVB Nasdaq
- SILO Nasdaq
- Market Cap
- ENVB 3.2M
- SILO 3.1M
- IPO Year
- ENVB N/A
- SILO N/A
- Fundamental
- Price
- ENVB $1.21
- SILO $0.45
- Analyst Decision
- ENVB Strong Buy
- SILO
- Analyst Count
- ENVB 1
- SILO 0
- Target Price
- ENVB $10.00
- SILO N/A
- AVG Volume (30 Days)
- ENVB 419.0K
- SILO 639.0K
- Earning Date
- ENVB 05-14-2025
- SILO 05-09-2025
- Dividend Yield
- ENVB N/A
- SILO N/A
- EPS Growth
- ENVB N/A
- SILO N/A
- EPS
- ENVB N/A
- SILO N/A
- Revenue
- ENVB N/A
- SILO $72,102.00
- Revenue This Year
- ENVB N/A
- SILO $1.86
- Revenue Next Year
- ENVB N/A
- SILO N/A
- P/E Ratio
- ENVB N/A
- SILO N/A
- Revenue Growth
- ENVB N/A
- SILO N/A
- 52 Week Low
- ENVB $1.01
- SILO $0.41
- 52 Week High
- ENVB $11.97
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- ENVB 38.00
- SILO 31.90
- Support Level
- ENVB $1.11
- SILO $0.41
- Resistance Level
- ENVB $1.31
- SILO $0.49
- Average True Range (ATR)
- ENVB 0.11
- SILO 0.06
- MACD
- ENVB 0.04
- SILO -0.00
- Stochastic Oscillator
- ENVB 26.33
- SILO 4.92
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.